Loratsepaami

Lorazepam is a short-acting depressant of the benzodiazepine class. First marketed by Wyeth Pharmaceuticals in the United States in 1977, it is prescribed for the short-term treatment of anxiety, insomnia, acute seizures, and sedation of hospitalized patients. It is characterized by its relatively rapid clearance compared to many other benzodiazepines. Like all benzodiazepines, lorazepam carries a significant risk of physical dependence and habit formation with repeated use.

Also known as: Tavor, Ativan, Temesta, Orfidal, Lorsilan, Loreev XR, O-Chloroxazepam

Classification

Chemical: Benzodiazepine
Chemical: Medicine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: Common
Tag: GABAergic
Tag: Habit-Forming
Tag: Muscle Relaxant
Tag: Sedative

Effects

Sedation
Muscle Relaxation
Respiratory Depression
Seizure Suppression
Anxiolytic
Sedative
Anxiety Suppression
Thought Deceleration
Information Processing Suppression
Euphoria
Amnesia
Compulsive Redosing
Disinhibition
Open Eye Visuals
Visual Fragmentation
Dulled Perception

Routes of Administration

Oral

Dosage

Heavy: 4 - 7.5 mg
Light: 0.1 – 0.5 mg
Common: 0.5 – 1.5 mg
Strong: 1.5 – 2 mg
Threshold: 0.25 mg

Duration

Onset: 0.08-0.5 h
Peak: 1-3 h
Offset: 6-12 h
After Effects: 12-24 h
Total Duration: 8-16 h

Intramuscular

Dosage

Common: 0.5-1 mg
Light: 0.25-0.5 mg
Strong: 1-2 mg

Duration

No data available for this section yet.

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu